Rigel Pharmaceuticals, Inc. (RIGL) Reports In-Line Q2 EPS
Tweet
Share
E-mailGet Alerts RIGL Hot Sheet
Price: $44.48 --0%
Revenue Growth %: +15.2%
Financial Fact:
Contract revenues from collaborations: 3.76M
Today's EPS Names:
ALZN, ASPU, USAU, More
Revenue Growth %: +15.2%
Financial Fact:
Contract revenues from collaborations: 3.76M
Today's EPS Names:
ALZN, ASPU, USAU, More
Join SI Premium – FREE
Rigel Pharmaceuticals, Inc. (NASDAQ: RIGL) reported Q2 EPS of ($0.35), in-line with the analyst estimate of ($0.35). Revenue for the quarter came in at $1.15 million versus the consensus estimate of $550 thousand.
For earnings history and earnings-related data on Rigel Pharmaceuticals, Inc. (RIGL) click here.
For earnings history and earnings-related data on Rigel Pharmaceuticals, Inc. (RIGL) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Lennar Corp. (LEN) Misses Q3 EPS by 10c
- S&P Global agrees to acquire blockchain security firm OpenZeppelin
- CoreWeave signs new compute contracts at $40M per megawatt pricing
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
